69 related articles for article (PubMed ID: 15378948)
21. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
Link MP; Shuster JJ; Donaldson SS; Berard CW; Murphy SB
N Engl J Med; 1997 Oct; 337(18):1259-66. PubMed ID: 9345074
[TBL] [Abstract][Full Text] [Related]
22. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
23. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
[TBL] [Abstract][Full Text] [Related]
24. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
[TBL] [Abstract][Full Text] [Related]
25. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
26. [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis].
Kharchenko VP; Datsenko PV; Panyshin GA; Sotnikov VM; Mel'nik IuD
Vopr Onkol; 2006; 52(5):531-7. PubMed ID: 17168361
[TBL] [Abstract][Full Text] [Related]
27. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
Hohaus S; Di Febo A; Storti S; Teofili L; Voso MT; Leone G
Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
[TBL] [Abstract][Full Text] [Related]
29. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the therapy of Hodgkin's disease in elderly patients. The Piemonte Hodgkin's Disease Register (PHDR).
Levis A
Hematol Oncol; 1993; 11 Suppl 1():78-84. PubMed ID: 7683625
[No Abstract] [Full Text] [Related]
31. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
32. Hodgkin's lymphoma in the elderly: a different disease in patients over 60.
Klimm B; Diehl V; Engert A
Oncology (Williston Park); 2007 Jul; 21(8):982-90; discussion 990, 996, 998 passim. PubMed ID: 17715698
[TBL] [Abstract][Full Text] [Related]
33. Bendamustine combined regimen for Hodgkin's lymphoma.
Venkatesan P
Lancet Oncol; 2016 Aug; 17(8):e326. PubMed ID: 27425812
[No Abstract] [Full Text] [Related]
34. Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial?
Landgren O; Andrén H; Nilsson B; Ekbom A; Björkholm M
Ann Oncol; 2005 May; 16(5):838-40. PubMed ID: 15802281
[No Abstract] [Full Text] [Related]
35. Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index.
Gisselbrecht C; Ferme C
Leuk Lymphoma; 1995; 15 Suppl 1():23-4. PubMed ID: 7767254
[No Abstract] [Full Text] [Related]
36. The challenges of Hodgkin lymphoma in the elderly.
Coiffier B
Oncology (Williston Park); 2008 Nov; 22(12):1388, 1393. PubMed ID: 19322948
[No Abstract] [Full Text] [Related]
37. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease.
Henry-Amar M; Somers R
Semin Oncol; 1990 Dec; 17(6):758-68. PubMed ID: 2251521
[No Abstract] [Full Text] [Related]
38. Prognostic factors in Hodgkin's disease: problems and pitfalls.
Phillips G
Leuk Lymphoma; 1995; 15 Suppl 1():43-5. PubMed ID: 7767260
[No Abstract] [Full Text] [Related]
39. [Statistical correlations of the duration of survival and prognostic factors in the group of patients with Hodgkin's disease].
Mierzwińska J; Gałecki J; Mykowiecka A
Nowotwory; 1990; 40(2):138-42. PubMed ID: 2274425
[TBL] [Abstract][Full Text] [Related]
40. Reevaluation of prognostic significance of symptoms in Hodgkin's disease.
Gobbi PG; Cavalli C; Gendarini A; Crema A; Ricevuti G; Federico M; Di Prisco U; Ascari E
Cancer; 1985 Dec; 56(12):2874-80. PubMed ID: 4052959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
